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Abstract 
Identification of Expression and Function of the Glucagon-like Peptide-1 Receptor in 
Gastrointestinal Smooth Muscle.  
Alexander T. May, Hongxia Wang, Sunila Mahavadi, John R. Grider, Karnam S. Murthy 
Department of Physiology and Biophysics, VCU Program in Enteric Neuromuscular 
Sciences, Virginia Commonwealth University, Richmond, Virginia Commonwealth 
University, Richmond, Virginia 
In response to ingestion of nutrients enteroendocrine L cells secrete a potent incretin 
hormone, glucagon-like peptide-1 (GLP-1) to enhance glucose-dependent release of 
insulin and regulate glucose metabolism.  Therapies related to GLP-1 (e.g., exendin-4) 
are currently approved for type 2 diabetes.  The GLP-1 receptor (GLP-1R) is expressed in 
cells of the gastrointestinal tract (enteric neurons, enterocytes) and elsewhere (pancreatic 
 cells, heart, and vascular smooth muscle).  In pancreatic  cells, GLP-1R are coupled 
to stimulatory G protein, Gs, generation of cAMP and activation of cAMP-dependent 
protein kinase.  Although a decrease in the motility of stomach and colon is commonly 
associated with diabetes, the expression and function of GLP-1R in gastrointestinal 
smooth muscle are not known.  Aim.  To test the hypothesis that GLP-1 regulates smooth 
muscle function by acting on GLP-1R expressed on smooth muscle.  Methods. Intestine 
and colon were removed from mice, and smooth muscle cells were isolated by 
collagenase digestion, and cultured in DMEM-10.  Expression of GLP-1R mRNA was 
measured by RT-PCR using specific primers and the expression of GLP-1R protein was 
measured by western blot using GLP-1R specific antibody (sc-66911 and 1:200 dilution).  
The effect of GLP-1 (7-36) amide on Gαs activation (by western blot using Gαs-GTP 
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specific antibody), cAMP formation  (by ELISA), and PKA activity (by a kinase assay 
using [32P]ATP) was examined in cultured smooth muscle cells. The effect of GLP-1 on 
basal activity and on acetylcholine (ACh)-induced contraction was measured in muscle 
strips and intact colon in organ bath experiments. Results.  Amplification of GLP-1R 
mRNA was obtained in mRNA isolated from mucosa derived from colon and intestine 
and also in mRNA obtained from tissue preparation devoid of mucosa suggesting 
expression of GLP-1R mRNA in mucosal as well as non-mucosal cells (enteric neurons 
or muscle cells) of the colon.  The specificity of GLP-1R primers was corroborated using 
mRNA from pancreatic  cells line (MIN-6) shown to express GLP-1R in our previous 
studies.  A similar pattern of GLP-1R protein expression was obtained with western blot.  
To identify the GLP-1R expression specifically in muscle cells devoid of other cells such 
as enteric neurons, expression was examined in cultured smooth muscle. Expression of 
GLP-1R mRNA was confirmed in these pure smooth muscle cell cultures of colon and 
intestine.  The role of GLP-1R in the regulation of smooth muscle function was analyzed 
in organ bath studies.  The addition of GLP-1 (1 nM-1 M) caused dose-dependent 
relaxation of basal tone in colonic muscle strips and relaxation of acetylcholine (ACh, 1 
M)-induced phasic activity and tonic contractions in both muscle strips and intact 
colon.  The effect of GLP-1 on ACh-induced contraction suggests a role of smooth 
muscle Gs-coupled GLP-1R in mediating relaxation.  In smooth muscle cells, GLP-1 (7-
36) amide caused activation of Gs, increased cAMP levels, and stimulated PKA 
activity. Conclusion. Colonic smooth muscle cells express GLP-1R, and GLP-1 inhibits 
both basal and acetylcholine-induced contraction. The GLP1-R is coupled to the 
heterotrimeric G protein, Gs. 
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CHAPTER 1: INTRODUCTION 
 
Anatomy and Function of the Gastrointestinal Tract 
 
 The gastrointestinal (GI) tract is a tubular series of organs arranged in a linear 
fashion spanning from the oral cavity to the anus. The physiological processes of 
digestion begin when the body is presented with olfactory or visual stimuli signaling an 
impending meal. Food begins to be broken down as it is chewed and swallowed, from 
where the bolus travels down the esophagus and into the stomach. Once mixed with 
hydrochloric acid in the stomach, chyme is systematically deposited into the proximal 
small intestine (duodenum), followed by migration distally into the jejunum and then the 
ileum. Chyme then leaves the small intestine and travels through the cecum, ascending 
colon, transverse colon, descending colon, and sigmoid colon, culminating in the rectum 
before it has amassed sufficiently to be excreted from the anus as feces.  
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Figure 1: Diagram of the Gastrointestinal Tract 
 
Figure 1. Diagram of the Gastrointestinal Tract. This figure provides a schematic of 
gastrointestinal anatomy. Food is swallowed and passes through the esophagus into the 
stomach, from where it is emptied into the small intestine. It passes into the colon and is 
then excreted. (Berne, 2008) 
 
Description of the Mucosa and Circular and Longitudinal Muscle Layers 
 The GI tract is arranged into layers with distinct structures and functions. 
Adjacent to the luminal space is the mucosa layer, containing an innermost epithelium, a 
middle lamina propria comprised of connective tissue, and an outer muscularis mucosa, a 
thin layer of smooth muscle. Surrounding the mucosa is the submucosa, a layer of loose 
collagenous tissue containing vasculature, neurons, and lymphatic vessels. The 
submucosa is surrounded by the muscularis propria, comprised of two smooth muscle 
layers. The muscularis propria contains an inner circular layer and outer longitudinal 
layer that mediate peristalsis in conjunction. The adventitia layer is the most superficial, 
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composed of supporting tissues, blood vessels, nerves, and adipose tissue. Within the 
peritoneal cavity, a serosa is also present, lined with mesothelium composed of simple 
squamous cells.  
 
Figure 2: Layers of the Gastrointestinal Tract 
 
 
Figure 2. Layers of the Gastrointestinal Tract. Panel A represents a longitudinal 
view of the gastrointestinal tract with layers exposed. Panel B displays a schematic of a 
slice of the tract from a cross-sectional view. (Berne, 2008). 
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Hormonal Regulation of Motility and Food Intake 
 The gastrointestinal tract is the largest endocrine system in the human body with 
respect to quantity of cells. Enteroendocrine cells (EECs) lie throughout the GI mucosa in 
crypts and villi and represent approximately 1% of gut epithelial cells. There are 
differentiated subgroups of EECs that secrete distinct combinations of hormones. In 
addition, EECs can be classified by morphology and position in mucosa. Open type EECs 
possess a bottle-neck shape with an apical elongation, allowing microvilli to face the 
intestine. Closed type EECs are located to the basal membrane and do not have luminal 
projections or microvilli.  
A cells are open-type EECs located in the stomach that secrete ghrelin. G cells are 
closed-type EECs in the duodenum and antrum of the stomach that secrete gastrin. D 
cells are open-type with long or short basal cytoplasmic processes and secrete 
somatostatin from the small intestine and gastric corpus and antrum regions of the 
stomach. L cells, which contain glucagon-like peptide-1 (GLP-1), GLP-2, and PYY, are 
open type and release their contents in response to ingested ingredients (Latorre, 2016).  
 Much is known about the specific hormones that mediate gastrointestinal motility, 
and their effects are well documented. Once released from A cells in the stomach, ghrelin 
increases food intake and feelings of hunger. Administration of ghrelin agonists has also 
been observed to increase gastric emptying in diabetic patients with gastroparesis. 
Peptide YY (PYY) is a gut hormone with structural similarities to neuropeptide Y (NPY) 
and reduces food intake in both humans and rodents once released from L cells. PYY is 
localized at its highest concentration along the distal aspects of the gastrointestinal tract 
but is also present in the proximal sections (Murphy, 2006). Cholecystokinin (CCK) is 
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secreted from I cells, a type of EEC (Latorre, 2016), in the small intestine and attenuates 
food intake, likely acting through CCK1 receptors localized to the vagus nerve. 
Pancreatic peptide (PP) is synthesized and secreted from the endocrine pancreas after 
meals, resulting in decreased food intake and delayed gastric emptying. Amylin is 
released simultaneously with insulin from pancreatic β-cells after meals, and reduces 
food intake when administered peripherally at supraphysiological doses.  
GLP-2 in peripheral circulation increases GI motility, but does not have an 
apparent effect on appetite. Oxyntomodulin is released post-prandially as a product of 
preproglucagon and reduces food intake. (Murphy, 2006). 5-hydroxytryptamine/serotonin 
(5-HT) is released from a variety of cells, including I cells, K cells, L cells, and 
enterochromaffin (EC) cells, and is thought to stimulate motility through both neuronal 
and mucosal mechanisms. Somatostatin is produced by D cells and stomach and small 
intestine and inhibits gastric acid secretion (Latorre , 2016). Glucose-dependent 
insulinotropic polypeptide (GIP) is released from duodenal K cells after meals. GIP has 
not been observed to influence food intake acutely, but it has been shown that GIP-
receptor knockout (KO) mice are resistant to obesity while subjected to high-fat diets. 
(Murphy, 2006) (Suzuki, 2017). 
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Figure 3: Schematic of a Typical Enteroendocrine Cell 
 
 
 Figure 3. Schematic of a Typical Enteroendocrine Cell. This figure provides a 
conceptual schematic of an EEC. Cell polarity is indicated by the distinct apical and 
basolateral aspects, with the apex adjacent to the gut lumen and the basolateral side 
adjacent to highly vascularized and innervated layers. Nutrients are sensed at the apical 
membrane, intracellular signaling occurs, and hormones are exocytosed from the 
basolateral membrane (Zietek, 2016). 
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Description of Incretins 
 The term ‘incretin’ originated in the early 1900s when clinicians first isolated 
glucose-lowering intestinal factors from gut extracts. The name references the ability of 
incretins to increase the insulinemic peak following orally administered glucose, 
compared with intravenous glucose infusion. ‘The incretin effect’ refers to this disparity 
in insulinotropic capabilities. 
 Food intake is the physiological stimulus for incretin release from 
enteroendocrine cells, and the primary effect of the incretin family is reduction of blood 
glucose levels. This effect is mediated by the regulation of hormonal pancreatic 
secretions, leading to inhibition of gastric emptying and reduction of appetite and food 
intake. GIP was the first incretin identified, and the failure of its inactivation to remove 
insulinotropic effects suggested the presence of other peptides with similar actions. GLP-
1 was identified years later after the preproglucagon gene was cloned and characterized 
on the long arm of human chromosome 2 (Cantini, 2016). 
 
Biochemistry, Production, and Secretion of GLP-1 
 Food intake is the primary stimulus for the release of GLP-1 from L cells, 
localized mostly in the ileum of the small intestine. Plasma GLP-1 levels increase 
minutes after a meal before digested food reaches the L cells, suggesting that GLP-1 
production is mediated by neural and endocrine stimulation instead of direct nutrient 
sensing by the intestinal walls. In fasted humans, plasma levels of active GLP-1 (7-36) 
amide tend to remain in the range of 5-10 pmol/liter. Plasma levels peak in the range of 
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15-50 pmol/liter after 30-120 minutes (Cantini, 2016). 
Enteroendocrine L cells synthesize a large precursor protein, preproglucagon, 
which is processed to produce GLP-1 as well as other biologically active peptides. The 
most common form of GLP-1 in circulation is the GLP-1 (7-36) amide (Murphy, 2006). 
GLP-1 (7-36) amide is the biologically active metabolite in circulation that causes the 
increase of glucose-dependent insulin secretion after binding to GLP-1R (Barale 2017). 
GLP-1 (7-36) amide is rapidly degraded by the enzyme dipeptidyl peptidase (DPP)-4 into 
GLP-1 (9-36) amide, the primary GLP-1 metabolite without the ability to interact with 
GLP-1R, and has a short half-life (Barale 2017), (Cantini 2016). The half-life of 
intravenously injected GLP-1 in humans is only 2-3 minutes.  
GLP-1 (7-36) amide is a peptide consisting of 30 amino acids after the alternative 
processing of preproglucagon. The preproglucagon gene is located in human 
chromosome 2q36-q37 and contains six exons and five introns. Exon 4 contains the entire 
coding sequence for GLP-1. In mammals, the preproglucagon gene is transcribed into an 
mRNA that yields a single 180-amino acid precursor. The post-translational processing 
undergone by preproglucagon is tissue-specific, with different prohormone convertase 
(PC) enzymes located in the pancreas, intestine, and brain.  
The proglucagon protein contains active peptides other than GLP-1, including 
glucagon, GLP-2, oxyntomodulin, and other fragments with unclear roles. PC1/3 is 
expressed primarily in the central nervous system and GI tract, yielding the products 
GLP-1, GLP-2, and oxyntomodulin. Pancreatic α cells contain high levels of a different 
convertase isoform, PC2, which is responsible for significant glucagon production in the 
pancreas, in addition to modest glucaon production in the brain. Pancreatic α cells also 
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express low levels of PC1/3, implying modest production of GLP-1 from pancreatic 
islets. 
The various isoforms of GLP-1 are produced by additional post-translational 
modification, specifically by cleavage of six amino acids from the N-terminus of GLP-1 
(1-37). The products exhibit varying degrees of activity and include GLP-1 (7-37) and 
GLP-1 (7-36) in addition to the C-terminal-amidated forms, GLP-1 (7-37) amide and 
GLP-1 (7-36) amide. The amide isoforms require further post-translational modification 
by a peptide-amidating monooxygenase. All isoforms mentioned are able to recognize 
and exert equipotent effects on pancreatic GLP-1R (Cantini, 2016) (Figure 4). 
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Figure 4. Diagram of GLP-1 Processing: From DNA to the Amino Acid Sequence 
(adapted from Cantini, 2016) 
 
 Figure 4. GLP-1 Processing. The preproglucagon gene contains six exons (E1, 
E2, E3, E4, E5, E6) and five introns. It is transcribed into mRNA and translated into the 
proglucagon precursor. The prohormone convertases, PC1/3 and PC2 perform tissue-
specific post-translational processing to generate different active peptides, including 
GLP-1, GLP-2, glucagon, oxyntomodulin, glicentin, glicentin-related polypeptide, major 
glucagon fragment, intervening peptide-1, and intervening peptide-2. Further post-
translational cleavage of six amino acids from the N-terminus of GLP-1 (1-37) produce 
the active forms, GLP-1 (7-37) and GLP-1 (7-36). The forms amidated at the C-terminus 
are produced by additional post-translational modifications from a peptide-amidating 
monooxygenase. Sites of cleavage by DPP-4 are noted by the dotted red line. 
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Characteristics of the Glucagon-like Peptide-1 Receptor 
 GLP-1R is a G-protein coupled receptor with seven transmembrane domains and 
463 amino acids. It contains a large hydrophilic extracellular domain at the N-terminus, 
which also contains a 23 amino acid leader sequence essential for the biosynthesis of the 
receptor. There are six cysteine residues at the N-terminus which are essential for ligand 
binding, in conjunction with other cysteine residues in the extracellular loop between 
transmembrane regions 1 and 3. Distinct domains within the third intracellular loop at the 
C-terminus are essential for selective binding of specific G proteins. The receptor enters 
the endoplasmic reticulum (ER) during maturation, where it undergoes N-linked 
glycosylation in specific amino acid residues. This process is associated with proper 
expression of GLP-1R at the plasma membrane (Donnelly, 2012) (Cantini, 2016). 
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Figure 5: Schematic of Typical G-protein Coupled Receptor 
 
Figure 5: Schematic of a Typical G-protein Coupled Receptor. This figure 
provides a representation of a typical GPCR, such as GLP1-R, in both inactivated (A) and 
activated (B) states (Alberts, 2008). There is an extracellular N-terminus, 7 
transmembrane domains, and an intrcellular C-terminus. The γ complex dissociates 
from the G subunit after activation by ligand binding.  
 
Known GLP-1R Expression 
 GLP-1R mRNA has been identified in the lung, pancreatic islets, stomach, 
kidney, hypothalamus, and heart. Studies failed to identify expression in adipose tissue, 
liver, or skeletal muscle. Expression of mRNA in these regions suggests the presence of 
translated GLP-1R protein. Interestingly, GLP-1R isoforms identified in the kidney and 
heart are suggested to be structural variants to the pancreatic classical receptor. In the 
pancreas, GLP-1R is expressed primarily in β cells and to a lesser degree in δ cells. The 
expression of the receptor in α cells is debated and unclear. Within the heart, GLP-1R is 
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expressed at the atrial level and sinoatrial myocytes, but not in the ventricular 
myocardium (Richards, 2014) (Kim, 2013). 
Physiological Effects of GLP-1 
 After secretion, GLP-1 (7-36) amide binds to a specific GLP-1R and causes 
tissue-specific responses (Barale 2017). The effects of GLP-1 in pancreatic β cells are 
well documented, although the underlying mechanisms are not well understood. GLP-1 
in pancreatic β cells has an insulinotropic effect, leading to instantaneous insulin 
secretion and lowered blood glucose levels. Some evidence suggests that GLP-1 induces 
insulin and zinc secretion from pancreatic β and δ cells, which would act on ATP-
dependent potassium channels to block glucagon secretion from α cells. It is unclear if 
GLP-1 acts directly on α cells, since GLP-1R expression has not been confirmed there 
(Franklin, 2005) (Tuduri, 2016). 
 In cardiovascular tissue, activation of GLP-1R by GLP-1 is thought to induce 
cardioprotective effects via activation of anti-apoptotic mechanisms in cardiomyocytes 
(Noyan-Ashraf, 2009) (Richards, 2014). Liraglutide, a GLP-1R agonist, was shown in 
mice to improve cardiomyocyte survival after induced ischemia, and it also resulted in 
sustained improvement of cardiac function after myocardial infarction. These effects are 
thought to be due to modulation of the expression of genes with known cardioprotective 
effects, including Nrf2, peroxisome proliferator-activated receptor, and heme oxygenase 
1, via activation of the second messengers Akt and glycogen synthase kinase. This would 
suggest a mechanism of cardiovascular GLP-1R distinct from pancreatic GLP-1R 
(Noyan-Ashraf, 2009). 
 In the human and mouse CNS, GLP-1R have been identified in the arcuate and 
 
22 
paraventricular nuclei in the hypothalamus, which are involved with regulation of 
appetite and satiety.  
G Protein Signaling 
G proteins are membrane-associated proteins that are usually classified as either 
‘small’ or ‘large/heterotrimeric.’ They are coupled with membrane-bound proteins known 
as G-protein coupled receptors (GPCRs), and the various relationships between G 
proteins and GPCRs mediate various signal transduction pathways. This study will focus 
on heterotrimeric G proteins. 
Heterotrimeric G proteins contain 3 subunits, classified as , , and . In the 
inactive conformation, the  subunit is bound to guanosine diphosphate (GDP) and forms 
a stable complex with the  and  subunits. Upon GPCR activation by an agonist, the 
receptor couples with its respective G protein, and the GDP bound to the  subunit is 
exchanged for guanosine triphosphate (GTP). Now bound to GTP and activated, the G-
GTP complex dissociates both from the GPCR and the G complex. The G-GTP or 
G complexes may then induce signal transduction by activating intracellular 
downstream effectors. The signal is ultimately terminated by the intrinsic GTPase activity 
of the  subunit, which hydrolyzes GTP to GDP and enables the re-association of the , 
, and  subunits, yielding the inactive heterotrimer. 
Specificity and selectivity of G protein signaling systems arise from the distinct 
heterotrimers formed by different isoforms of the subunits. In humans, there are 21 
known isoforms encoded by 16 G subunit genes, 6 known G subunits encoded by 5 
genes, and 12 known G isoforms, resulting in over 700 combinations of G 
heterotrimers. These heterotrimers are further classified into 4 main classes: Gs, Gi/o, 
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Gq/11, and G12/13, all with distinct downstream effects. (Ross and Gilman, 1980) 
(Moreira, 2014) (Yu, 2017) (Duc, 2017)  
Rationale 
 Glucagon-like peptide-1 is an incretin peptide hormone secreted in response to 
nutrient ingestion. It increases insulin secretion, decreases glucagon secretion, and 
reduces gastrointestinal motility. The GLP1-R is coupled to Gs proteins in pancreatic 
 cells and activates the adenylyl cyclase/cAMP/PKA pathway. However, the presence 
of the GLP1-R is gastrointestinal smooth muscle is not known, nor is the mechanism of 
action of GLP-1 in gastrointestinal smooth muscle. The aim of this study is to test the 
hypothesis that GLP-1 regulates smooth muscle function by acting on GLP-1R 
expressed on smooth muscle. 
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CHAPTER 2: MATERIALS AND METHODS 
Reagents 
 Antibodies for GLP-1R, GLP-1R (D6) and GLP-1R (H-55) were obtained from 
Santa Cruz Biotechnologies, Inc. (Dallas, TX); [35P]ATP was obtained from NEN Life 
Sciences (Boston, MA); NF449 (4,4',4'',4'''-[Carbonylbis(imino-5,1,3-benzenetriyl-
bis(carbonylimino))]tetrakis-1,3-benzenedisulfonic acid), GLP-1(7-37), and GLP-1(7-36) 
amide were obtained from Tocris Bioscience (Bristol, United Kingdom); (RNAqueousTM 
kit and TRIzol® Reagent were obtained from Ambion (Austin, TX). High Capacity 
cDNA Reverse Transcription Kit was obtained from Applied Biosystems (Foster City, 
CA); Q5® Reaction Buffer, Q5® High GC Enhancer, Deoxynucleotide (dNTP) Solution 
Mix, Q5® High-Fidelity DNA Polymerase were obtained from New England Biolabs 
(Ipswitch, MA); Western blotting materials, 4x Laemmli Sample Buffer, and DCTM 
Protein Assay Reagents were obtained from Bio-Rad Laboratories (Hercules, CA); 
SuperSignal® West Pico Chemiluminescent Substrate, Dulbecco’s Modified Eagle 
Medium, and Trypsin-EDTA (0.25%) with phenol red were obtained from ThermoFisher 
Scientific (Waltham, MA); Collagenase CLS type II and soybean trypsin inhibitor were 
obtained from Worthington (Freehold, NJ); T-PER® Tissue Protein Extraction Reagent 
was obtained from Thermo Scientific (Rockford, IL); Monoclonal Anti-cAMP Antibody 
Based Direct cAMP ELISA Kit was obtained from NewEast Biosciences (Malvern, PA); 
All other chemicals were obtained from Sigma-Aldrich (St. Louis, MO). 
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Animals 
 Wild-type mice (C57BL/6) were used purchased from Jackson Laboratories 
(Sacramento, California).  The mice were housed in an animal facility directed by the 
Division of Animal Resources at Virginia Commonwealth University. Mice were 
subjected to 12-hour light and 12-hour dark cycles with food and water provided. Mice 
were euthanized by asphyxiation by carbon dioxide (CO2) under approval by the 
Institutional Animal Care and Use committee of Virginia Commonwealth University. 
 
Preparation of Mouse Intestine and Colon 
 Mice were euthanized by CO2 inhalation, and they were carefully observed to 
ensure cessation of life. Abdominal incisions were made vertically, and the small 
intestine and colon were removed and placed into beakers filled with a smooth muscle 
buffer (SMB) consisting of NaCl 120 mM, KCl 4 mM, KH2PO4 2.6 mM, CaCl2 2.0 mM, 
MgCl2 0.6 mM, HEPES (N-2-hydroxyethylpiperazine-N’ 2-ethanesulfonic acid) 25 mM, 
glucose 14 mM, and Basic Eagle Medium (essential amino mixture) 2.1% (pH 7.4). 
Luminal contents of the intestinal and colonic tubes were flushed with a blunt syringe 
filled with SMB. The tubes were opened along the mesenteric border with scissors. The 
mucosal layer, containing EEC, was carefully separated from the smooth muscle layer, 
containing smooth muscle cells, ICC, and the myenteric plexus, using the rounded edge 
of forceps. For protein and RNA extraction, tissues were homogenized on ice in a 
phosphate-buffered saline (PBS) solution supplemented with protease inhibitors. For 
preparation of cell culture, smooth muscle layer tissues were placed in SMB. All tissues 
were used for experiments immediately. 
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Preparation of Dispersed Small Intestine and Colon Smooth Muscle Cells 
 Smooth muscle cells were isolated from colonic and small intestinal smooth 
muscle by sequential enzymatic digestion of muscle strips, filtration, and centrifugation. 
Tissues were chopped with scissors and incubated at 35C for 20-30 minutes in SMB 
containing 0.1% collagenase (300 U/ml) and 0.01% soybean trypsin inhibitor (w/v). The 
SMB containing the tissue received 100% oxygen during the entire procedure. Partially 
digested tissues were washed twice with collagenase-free SMB and were then permitted 
to disperse spontaneously in collagenase-free DMEM. Smooth muscle cells were then 
harvested via filtration using 500 μm Nitex and centrifuged at 2000 rpm for 10 minutes. 
To wash the cells, the supernatant was aspirated, cells were resuspended in fresh DMEM, 
and the mixture was centrifuged again at 2000 rpm for 10 minutes. Cells were washed 
twice before being prepared for culture. 
 
Preparation of Cultured Small Intestine and Colon Smooth Muscle Cells 
 Dispersed smooth muscle cells isolated from mouse small intestine and colon 
were resuspended in DMEM-10 containing penicillin (200 U/ml), streptomycin (200 
µg/ml), gentamycin (100 µg/ml), amphotericin B (2.5 µg/ml) and 10% fetal bovine 
serum. Using proper sterile protocol, cells were plated at a concentration of 
approximately 5 X 105 cells/mL and stored at 37°C in an incubator with 10% CO2. 
DMEM-10 was replaced every 1-3 days as needed until 80-90% confluence was reached. 
Primary culture smooth muscle cells were trypsinized (Trypsin-EDTA, 0.25%) and 
observed via microscopy for detachment. The mixture was collected via autopipette and 
DMEM-10 was added to cease trypsinization. The supernatant was aspirated, cells were 
 
27 
resuspended in DMEM-10, and the cells were either used immediately for experiments or 
replated at a 2:1 dilution to continue culture under the same conditions as previously 
described. Experiments were performed on cells in the first and second passage. 
 
Protein and mRNA Extraction from Smooth Muscle Cells 
 To obtain protein, cells or tissue were isolated and mixed into T-PER containing a 
phosphatase inhibitor cocktail (cantharidin, bromotetramisole, and microcytin-LR) (1:200 
dilution) and a protease inhibitor cocktail (4-(2-aminoethyl)benzenesulfonyl fluoride 
hydrochloride, leupeptin, bestatin, pepstatin, and E-64) (1:200). 4 mL of T-PER were 
used per gram of tissue, and the mixture was allowed to incubate at room temperature for 
15 minutes. Tissues or cells were homogenized and then allowed to incubate for 15 
minutes at room temperature. The mixture was homogenized a second time and then 
separated by centrifugation for 20 minutes at 12,000 rpm for 20 minutes. The supernatant 
containing extracted protein was then transferred to a new tube, and protein concentration 
was determined via Bio-Rad DC Protein Assay Kit against a bovine serum albumin 
standard curve.  
 To obtain mRNA from tissue, 0.5 mL of TRIzol was added to 50-100 mg of 
tissue. The mixture was permitted to incubate at room temperature for 5 minutes, and 0.2 
mL chloroform was added. After violent mixing, the solution was incubated at room 
temperature for 2-3 minutes and then centrifuged at 12000 g at 4°C for 15 minutes. The 
upper aqueous phase was transferred to a new tube, and the 0.2 mL of chloroform was 
added. The mixture was incubated and centrifuged a second time as previously described. 
Next, 0.5 mL of 2-propanol was added, the solution was mixed, and the mixture was 
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incubated at room temperature for 10 minutes. The tube was centrifuged at 12000 g for 
15 minutes at 4°C. The supernatant was discarded and 1 mL of cold ethanol (75%) was 
used to resuspend the pellet. The mixture was again centrifuged at 12000 g for 15 
minutes at 4°C. The supernatant was aspirated with care taken to leave the pellet intact, 
which was allowed to air dry at room temperature for 15 minutes. Total RNA was then 
dissolved into 0.1% diethylpyrocarbonate (DEPC)-treated water, and concentration was 
determined via spectrophotometry. 
 RNA was obtained from cultured smooth muscle cells using guanidinium-based 
lysis and glass fiber filter separation with the RNAqueous Total RNA isolation kit as 
described by the included protocol.  
  
RT-PCR Analysis of Mouse Colon and Small Intestine Mucosa and Smooth Muscle 
 Specific primers for GLP-1R were designed to span across exons of sequences 
homologous in mice and humans. The primer sequences for mouse GLP-1R were as 
follows: Forward 5’-CCC GCC CTC AGG GTA CCA CGG T-3’ and Reverse 5’-TCA 
GGA AAG TTT CTC TCC CCT C-3’, yielding a fragment of 346 bp (obtained from 
Invitrogen, Carlsbad, CA). Sequences for glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), a housekeeping gene with known expression in smooth muscle cells (Perrotta, 
2017), primers were as follows: Forward 5’-AGA AAC CTG CCA AGT ATG ATG-3’ 
and Reverse 5’-GGA GTT GCT GTT GAA GTC G-3’. The High Capacity cDNA 
Reverse Transcription Kit was used to synthesize cDNA. The reaction mixture was 
prepared as described by the given protocol using 1 μg of RNA. Negative controls were 
created by substituting the reverse transcriptase enzyme with an equal volume of 
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DNase/RNase-free water. An Eppendorf Vapo Protect Mastercycler was used for thermal 
cycling with the following conditions: 10 minutes at 25°C, 120 minutes at 37°C, 5 
minutes at 85°C, and a hold at 4°C as needed.  
 PCR products were generated using primers specific for GLP-1R and GAPDH as 
previously described. The PCR reaction mixture was prepared as follows: 5 μL of 5x Q5 
Reaction buffer, 0.5 μL of 10 mM dNTP, 1.25 μL of 10 μM forward primer, 1.25 μL of 
10 μM reverse primer, 0.25 μL of Q5 DNA polymerase, 2 μL of cDNA, and 9.75 μL of 
DNase/RNase-free water. Due to the GC-rich content of the forward and reverse GLP-1R 
primers, 5 μL of 5x Q5 GC Enhancer was also added for a total reaction volume of 25 
μL. Thermal cycling conditions were determined empirically, with the following 
conditions used to generate GLP-1R PCR products: initial denaturation step at 95°C for 3 
minutes; 37 cycles of 95°C for 30 seconds, 55°C for 45 seconds, and 72°C for 1 minute; 
final extension step at 72°C for 10 minutes; hold at 4°C as needed. The following 
conditions were used to generate GAPDH PCR products: initial denaturation step at 95°C 
for 3 minutes; 30 cycles of 95°C for 30 seconds, 55°C for 45 seconds, and 72°C for 1 
minute; final extension step at 72°C for 10 minutes; hold at 4°C as needed. The PCR 
products were separated by electrophoresis in a 1.2% agarose gel at 100 volts in the 
presence of ethidium bromide. Bands were visualized by ultraviolet fluorescence and 
recorded with a Bio-Rad Gel Doc EZ Imager. 
 
Western Blot Analysis 
 Protein was extracted from colon and intestine tissues, with concentration 
determined by protein assay. Tris/Glycine sodium dodecyl sulfate-polyacrylamide gels 
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for electrophoresis (SDS-PAGE) were made with the following components: 2.0 mL of 
ddH20, 1.3 mL of 30% acrylamide mix, 1.3 mL of 1.5 M Tris (pH=8.8), 0.05 mL of 10% 
SDS, 0.05 mL of 10% ammonium persulfate solution (APS), and 0.002 mL of TEMED. 
After polymerization, a stack buffer (0.68 mL of ddH20, 0.17 mL of 30% acrylamide 
mix, 0.13 mL of 1.0 M Tris (pH=6.8), 0.01 mL of 10% SDS, 0.01 mL of 10% (APS), and 
0.001 mL of TEMED) was added and allowed to polymerize. 40 μg of protein were used 
per sample, which was diluted 3:1 with 4x Laemmli Sample Buffer (with 10% 2-
mercaptoethanol). β-actin was used as a positive control. Samples were heated at 95°C 
for 5 minutes, loaded into wells, and separated via SDS-PAGE for 30-60 minutes at 75 V 
through the stack buffer and then for 30-90 minutes at 100 V through the resolving 
buffer. Protein bands were transferred onto a nitrocellulose membrane via Bio-Rad 
Trans-Blot Turbo Transfer system. The membrane was then blocked with 5% (w/v) non-
fat dried milk/TBS-T (Tris-buffered saline [pH = 7.6] and 0.1% Tween-20) for 1 hour at 
room temperature.  
 The membrane was incubated overnight at 4°C with a primary antibody specific 
for GLP-1R (Santa Cruz Biotechnology, sc-390774, 1:200 in TBS-T/1% non-fat dried 
milk) and then washed thrice with TBS-T. It was then incubated for 1 hour at room 
temperature with horseradish peroxidase-conjugated goat anti-mouse secondary antibody 
(1:2000 in TBS-T/1% non-fat dried milk). The membrane was washed thrice with TBS-
T, and immunoreactive proteins were visualized using the SuperSignal West Pico 
Chemiluminescent substrate. Membranes were covered in clear plastic wrap, exposed to 
film, and developed. 
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Gs Activation Assay.  
 Activation of Gs in response to GLP-1 was analyzed by western blot using an 
antibody that specifically recognizes the activated (GTP-bound) Gαs subunit (NewEast 
Biosciences; catalogue # 80801).  Muscle cells in culture were treated with GLP-1 (7-36) 
amide (1 µM) for 5 minutes in the presence or absence of Gs activation inhibitor, NF449 
(10 µM) (Hohenegger, 1997).  In some experiments, muscle cells were treated with 1 µM 
vasoactive intestinal peptide (VIP), a known ligand for Gs-coupled VPAC2 receptor, for 5 
minutes.  At the end of 5-minute incubation, medium was removed and muscle cells were 
solubilized on ice for one hour in medium containing 20 mM Tri-HCl (pH 8.0), 1 mM 
DTT, 100 mM NaCl, 0.5% sodium dodecyl sulfate, 0.75% deoxycholate, 1 mM PMSF, 
10 g/ml of leupeptin and 100 g/ml of aprotinin.  The proteins in the lysate were 
resolved by SDS/PAGE and electrophoretically transferred onto nitrocellulose 
membranes.  The membranes were incubated for 12 h with anti-Gαs-GTP antibody 
(1:1500) and then for 1 h with horseradish peroxidase-conjugated secondary antibody 
(1:5000).  The protein bands were identified by enhanced chemiluminescence reagent.   
 
Generation of cAMP in Smooth Muscle 
 Cyclic AMP was measured by a competitive ELISA using a monoclonal anti-
cAMP antibody-based direct cAMP assay kit following the protocol provide by NewEast 
Biosciences (catalogue # 80203). Muscle cells in culture were treated with GLP-1 (7-36) 
amide (1 µM) for 5 minutes in the presence or absence of Gs activation inhibitor, NF449 
(10 µM).  In some experiments, muscle cells were treated with 1 µM VIP for 5 minutes. 
100 µM of isobutyl methyl xanthine was used in the incubation to prevent cAMP 
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hydrolysis.  Briefly, a 96-well plate was coated with goat-anti-mouse serum. cAMP from 
colonic smooth muscle extracts were competitively bound to the monoclonal anti-cAMP 
antibody in the presence of known amounts of cAMP-conjugated horseradish peroxidase, 
which were used to generate a standard curve. The plate was read on a Victor2 1420 
Multi-Level microplate reader at 450 nm. Optical density readings were used to calculate 
the concentration of cAMP in samples based on the standard curve.  Results were 
expressed as cAMP in pmol/mg protein.  
 
Activation of PKA in Colonic Smooth Muscle 
 Cyclic AMP-dependent protein kinase activity was measured in an in vitro kinase 
assay using PKA-selective substrate peptide kemptide and [32P]ATP. Muscle cells in 
culture were treated with GLP-1 (7-36) amide (1 µM) for 5 minutes in the presence or 
absence of Gs activation inhibitor, NF449 (10 µM).  In some experiments, muscle cells 
were treated with 1 µM VIP for 5 minutes. 100 µM of isobutyl methyl xanthine was used 
in the incubation to prevent cAMP hydrolysis. After a 5-minute incubation period, cells 
in the plate were rinsed with a medium containing 50 mM TrisHCl (pH 7.4), 10 mM 
EDTA, 0.5 mM IBMX, 10 mM 2-mercaptoethanol, and 100 mM NaCl, and were then 
homogenized in 0.5 mL of ice-cold medium. The mixture was separated by centrifugation 
at 48,000 g for 15 minutes. The supernatant was transferred to a new tube and used as a 
source for protein kinase. 20 μL of supernatant, containing 50 μg of protein, was used to 
initiate an assay in a medium containing 50 mM Tris, 20 mM magnesium acetate, 200 
μM [35P]ATP, 100 μM IBMX, 150 μM kemptide [LRRASG], a PKA substrate, and 0.25 
mg/mL BSA in the presence and absence of 5 μM cAMP. The reaction mixtures were 
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incubated at 35-37°C for 30 minutes and the reaction was stopped by spotting the 
reaction mixture onto a phosphocellulose filter discs. The filters were washed 3-4 times 
with 75 mM H2PO4 and then dried before transferring to vials for radioactive counting 
using a beta counter.  Results were expressed as a ratio activity in the presence or absence 
of cAMP.   
 
Smooth Muscle Strip Preparation 
 Mice were euthanized as previously described, and colons were removed and 
immediately washed and flushed Krebs solution containing 118 mM NaCl, 4.8 mM KCl, 
1mM MgSO4, 1.15 mM NaH2PO4, 15 mM NaHCO3, 10.5 mM Glucose and 2.5 mM 
CaCl2 (95% O2/5%CO2, pH 7.4). Colons were cut into segments approximately 1 cm in 
length, leaving some tubes intact while cutting others along the longitudinal axis. Intact 
segments were tied at each end with silk thread using care not to obstruct the lumen. The 
tissues were mounted between a glass rod and FT-03C isometric transducer (Grass 
Technologies, East Warwick, RI), oriented near the bottom of the 5 mL well (Radnoti, 
Monrovia, CA) to ensure constant submersion in Krebs buffer. Water was pumped 
constantly through the jackets surrounding the wells at 37°C to maintain constant 
temperature in the bath. Signals from the transducer were amplified by an Octal Bridge 
Amplifier (AD Instruments, Colorado Springs, CO), transmitted to a Powerlab 8/35 with 
Grass Adaptor unit, and recorded with ADInstruments LabChart Pro7 software. Force 
was recorded in grams (transduced from mV), and the transducer was calibrated with a 2-
point curve. 
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Effects of GLP-1 on Spontaneous Phasic and Acetylcholine-induced Contractions 
 Intact colon segments were prepared as previously described. All tubes were 
raised to 1 gram of tension and were then allowed to equilibrate in Krebs buffer for 45 
minutes. Tubes were washed out with fresh Krebs every 15 minutes during equilibration. 
Contraction was induced with acetylcholine (ACh) at a concentration of 1 μM. GLP-1 (7-
37) and GLP-1 (7-36) amide were added at target concentrations between 1 nM and 1 
μM. Measurements were taken prior to administration of ACh, during the plateau after 
ACh-induced contraction, and during the plateau after GLP-1 administration, and they 
were averaged to account for naturally occurring variations in smooth muscle. Samples 
were washed to encourage return to baseline tension. 
Statistical Analysis 
 Results were expressed as means ± standard error of the mean of n experiments. 
Experiments were designed to compare treatment to control conditions, with each 
individual strip serving as its own control. Paired t-tests were conducted in GraphPad 
Software Prism 6 (La Jolla, CA) with significance set at P<0.05 and denoted with “*”. 
Each experiment was performed on tissues obtained from different animals. 
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CHAPTER 3: RESULTS 
 
Expression of GLP-1R mRNA 
 Muscle and mucosal layers were isolated from the colon and small intestine of 
mice. RNA was extracted and reversibly transcribed to synthesize cDNA, which was then 
amplified via PCR. Specific primers for GLP-1R were used to yield fragments spanning 
346 bp in length. Pancreatic β cells (MIN6 cell line) and islets of Langerhans have known 
expression of GLP-1R and were used as positive controls in tissue. GAPDH was used as 
a housekeeping gene. Negative controls were made by substituting the reverse 
transcriptase enzyme for an equal volume of water to check for genomic DNA 
contamination. Expression of GLP-1 mRNA was observed in both mucosa and muscle 
layers of both small intestine and colon. Results are demonstrated in Figure 6. 
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Figure 6: Expression of GLP-1R mRNA in Small Intestine and Colon Tissue 
A)
 
B) 
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C) 
 
 
Figure 6. Expression of GLP-1R mRNA. A) This figure demonstrates expression of 
GLP-1R mRNA in mouse colon muscle and mucosa layers as well as small intestine 
muscle and mucosa layers. Bands are present in all lanes, including MIN6 and islets, the 
positive controls. B) This shows an example of RT-PCR experiments conducted in the 
small intestine. Bands are present in the intestinal muscle and mucosa lanes as well as the 
GAPDH lanes. No bands are present in the negative control lanes (absence of reverse 
transcriptase enzyme), suggesting lack of genomic DNA contamination. C) This shows 
an example of RT-PCR experiments conducted in the colon. Bands are present in the 
intestinal muscle lane as well as the GAPDH lanes. Expression was not observed in 
colonic mucosa in the experiment. No bands are present in the negative control lanes 
(absence of reverse transcriptase enzyme), suggesting lack of genomic DNA 
contamination. 
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Expression of GLP-1R Protein 
 Muscle and mucosal layers were isolated from the colon and small intestine of 
mice. Protein was extracted and quantified against a bovine serum albumin standard 
curve. Specific antibodies for GLP-1R were used to detect the protein target protein, 
sized 56 KDa. The pancreas has known expression of GLP-1R and was used as a positive 
control in tissue. β-actin was used as a loading control. Expression of GLP-1 protein was 
observed consistently in the muscle layers of both small intestine and colon. Results are 
demonstrated in Figure 7. 
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Figure 7: Expression of GLP-1R Protein 
 
  
 
 
 
 
 
Figure 7. Expression of GLP-1R Protein. The figure demonstrates expression of GLP-
1R in small intestine and colon muscle and mucosa. The top panel demonstrates 
expression of GLP-1R protein at 56 kDa in the muscle and mucosa layers of both colon 
and intestine. The bottom panel shows expression of the loading control, -actin, in all 
four samples. 
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Expression of GLP-1R in Smooth Muscle Cells 
 The aim of this study was to determine presence of GLP-1R on smooth muscle 
cells. The muscle layer of the gastrointestinal tract contains various other cell types, 
including enteric neurons and interstitial cells of Cajal. To address this, smooth muscle 
cells devoid of other cell types were isolated, cultured, and used to identify GLP-1R 
expression as well as the signaling pathway activated by GLP-1R in smooth muscle cells. 
RNA was extracted, reversibly transcribed, and amplified via PCR using specific primers. 
mRNA expression was consistent with results in tissue as previously described. Smooth 
muscle cells in the colon and small intestine were shown to express GLP-1R mRNA. 
Results are demonstrated in Figure 8. 
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Figure 8: Expression of GLP-1R in Smooth Muscle Cells 
 
 
 
 
 Figure 8. Expression of GLP-1R in Smooth Muscle Cells. The figure shows 
intestinal expression from 3 different experiments and colonic expression from 5 
different experiments. The bottom panel displays an example of a negative control, where 
water was substituted for the reverse transcriptase enzyme. Bands appear at the expected 
base pair length. 
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Activation of Gas by GLP-1 in Smooth Muscle Cells 
 Previous studies have shown that GLP-1 receptors are coupled to activation of Gs 
proteins in pancreatic beta cells.  We examined whether Gs proteins are activated in 
response to GLP-1(7-36) amide in western blot using an antibody that specifically bind 
activatde (GTP-bound) Gαs subunit.  Addition of 1 µM GLP-1(7-36) amide caused a 3 
fold increase in the activation of Gs suggesting that GLP-1 receptors in smooth muscle 
are coupled to activation of Gs.  This was further examined using a selective inhibitor 
(NF449).  The effect of GLP-1 in Gs activation was blocked in the presence of NF449.  
Control studied showed that VIP, a ligand known to activate Gs-coupled VPAC2 
receptors, also stimulated Gs. The extent Gs stimulation y GLP-1 and VIP appears 
similar.   These results suggest that in smooth muscle cells, GLP-1R are coupled to Gs 
proteins similar to pancreatic β cells. Results are demonstrated in Figure 9. 
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Figure 9: Activation of Gas by GLP-1 in Smooth Muscle Cells 
 
 Figure 9.  Gs activation by GLP-1.  Muscle cells were treated with 1 µM GLP-1 
(7-36) amide in the presence or absence of Gs activator, NF449 (10 µM).  In some 
experiments, cells were treated with 1 µM of VIP.  Activation of Gs was measured in a 
western blot analysis using an antibody selective for GTP-bound Gαs.  The density of 
bands was calculated by image analysis.  A representative image of 3 separate 
experiments is shown in the figure.   
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Increase in cAMP Levels by GLP-1 in Smooth Muscle Cells 
 Consistent with activation of Gs, treatment of cells with GLP-1(7-36) amide 
significantly increased cAMP levels compared to basal levels.  The effect of GLP-1 on 
cAMP levels was significantly inhibited by treatment of cells with GLP-1 in the presence 
of 10 µM NF449, an inhibitor of Gs activity.  The effect of NF449 on GLP-1-induced 
cAMP levels is consistent with its inhibitory effect on GLP-induced Gs activity.  VIP 
also caused a stimulation in cAMP levels and the results are consistent with its effect on 
Gs-coupled VPAC2 receptors in smooth muscle cells.  Results are demonstrated in 
Figure 10. 
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Figure 10: Increase in cAMP Levels by GLP-1 in Smooth Muscle Cells 
 
 Figure 10.  GLP-1 induced increase in cAMP levels.  Muscle cells in culture 
were treated with GLP-1(7-36) amide in the presence or absence of 10 µM NF449.  In 
some experiments cells were treated with 1 µM VIP.  cAMP was measured by ELISA as 
described in the Methods.  Results are expressed as pmol of cAMP/mg protein.  Values 
are mean ± SEM of 4 separate experiments 
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Gas-dependent Activation of PKA by GLP-1 in Smooth Muscle Cells 
 Stimulation of Gs and increase in cAMP leads to stimulation PKA activity.  
Treatment of cells with GLP-1 caused a significant increase in PKA activity and the 
stimulation was attenuated in the presence of Gs inhibitor, NF449.  The effect of NF449 
is consistent with its inhibitory effect on Gs activation and cAMP generation.  VIP also 
caused am increase in PKA activity.  These results suggest that in smooth muscle cells, 
GLP-1R are coupled to the Gs/cAMP/PKA pathway, similar to that of VIP. Results are 
demonstrated in Figure 11. 
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Figure 11: Gas-dependent Activation of PKA by GLP-1 in Smooth Muscle Cells 
 
 
 Figure 11.  GLP-1 induced increase in cAMP-Dependent protein kinase (PKA) 
activity.  Muscle cells in culture were treated with GLP-1(7-36) amide in the presence or 
absence of 10 µM NF449.  In some experiments cells were treated with 1 µM VIP.  PKA 
activity was measured in the lysates using kemptide and [32P]ATP in the presence or 
absence of cAMP as described in the Methods.  Results are expressed as ratio of PKA 
activity in the absence or presence of cAMP (-cAMP/+ cAMP).  Values are mean ± SEM 
of 3 separate experiments 
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Inhibition of Spontaneous Phasic Activity by GLP-1 in Colon 
 The effects of GLP-1 (7-36) amide on spontaneous phasic activity in the mouse 
colon were observed using intact colon segments in an organ bath equipped with a force 
transducer. The effects of GLP-1 on both basal and agonist-induced colonic muscle 
contraction were examined. GLP-1 (7-36) amide was shown to inhibit spontaneous 
phasic activity at a concentration of 1 μM. Results are demonstrated in Figure 12. 
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Figure 12: Inhibition of Spontaneous Phasic Activity by GLP-1 in Colon 
 
 
 
 
 Figure 12. Inhibition of Spontaneous Phasic Activity by GLP-1 in Colon. The 
figure displays a tracing from an intact colon segment in an organ bath. The left side of 
the panel shows baseline spontaneous phasic activity with consistent frequency and 
amplitude. Addition of GLP-1 (7-36) amide at a concentration of 1 μM immediately 
causes an inhibition of the amplitude of spontaneous contractions. The vertical bar 
represents 0.1 grams of force, and the horizontal bar represents 10 seconds. 
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Inhibition and Relaxation of Agonist-induced Tone by GLP-1 in Colon 
 The effects of GLP-1 (7-36) amide on agonist-induced tone in the mouse colon 
were observed using intact colon segments in an organ bath equipped with a force 
transducer. The effects of GLP-1 on both basal and agonist-induced colonic muscle 
contraction were examined. Contraction was induced by ACh at 1 μM, and GLP-1 (7-36) 
amide was added to the organ bath at 1 μM after tension plateaued.  Relaxation was 
observed immediately after addition of GLP-1, suggesting a relaxant effect on smooth 
muscle. Results are demonstrated in Figure 13. 
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Figure 13: Inhibition and Relaxation of Agonist-induced Tone by GLP-1 in Colon 
 
 
 
 Figure 13. Inhibition and Relaxation of Agonist-induced Tone by GLP-1 in 
Colon. Contraction was induced by ACh at 1 μM, and GLP-1 (7-36) amide was added to 
the organ bath at 1 μM after tension plateaued.  Relaxation was observed immediately 
after addition of GLP-1, suggesting a relaxant effect on smooth muscle, and decrease in 
tone by approximately 40% was observed. The horizontal line represents 1 minute, and 
the vertical line represents 1 gram of tension. GLP-1 exerts a clear relaxant effect on 
smooth muscle on tissues contracted by agonists. Mean relaxation in terms of percentage 
of peak contracted tension = 22.6%±4.6, n=4. 
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CHAPTER 4: DISCUSSION 
 
 The aim of this study was to examine the presence and function of the glucagon-
like peptide-1 receptor in gastrointestinal smooth muscle. GLP-1 is released after meals 
in response to stimuli such as glucose, lipid digestion products, amino acids, bile salts, 
and free fatty acids. Enteroendocrine cells then secrete hormones such as GLP-1 into the 
bloodstream with a host of effects on factors such as gastrointestinal motility, secretion, 
and energy metabolism. Expression of the GLP-1R has been identified throughout the 
human body, both centrally and peripherally, and many of its effects are well 
documented. GLP-1 is a potent insulinotropic hormone, assisting with the regulation of 
postprandial glucose homeostasis. Activation of GLP-1R results in increased insulin 
secretion and decreased glucagon secretion, decreased gastric emptying and motility, and 
increased satiety (Latorre, 2016) (Cantini, 2016). 
 Clinicians have identified the therapeutic potential of GLP-1 and its analogues for 
the treatment of type 2 diabetes mellitus due its insulinotropic effects. Patients with type 
2 diabetes have a significantly decreased incretin secretory response after eating, 
resulting in hyperglycemic conditions in postprandial and fasted states. While the effects 
of GLP-1 secretion seem promising, the efficacy of GLP-1 as a long-term treatment 
option is limited by its rapid life; the peptide is degraded by DPP-4 within minutes of 
entering circulation. Analogues such as exendin-based therapies, DPP-4 resistant 
analogues, and human GLP-1 analogues are being explored due to the potential of a 
prolonged therapeutic effect. Currently, commercially available analogues include 
exanatide, exanatide once weekly, and liraglutide.  
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 Interestingly, augmentation of the incretin system results in downregulation of 
glucagon secretion from pancreatic α cells, possibly resulting in more stability in blood 
glucose levels. While these properties are promising, very little is known about the 
distribution of GLP-1R throughout GI smooth muscle. In addition, the mechanisms by 
which the known properties of GLP-1 act are not understand. By identifying enzymes, 
substrates, and signaling molecules involved with the response, researchers improve their 
chances of identifying specific targets that might be useful for inducing a longer lasting 
insulinotropic response.  
 This study has identified Gαs as the G protein coupled with the GLP-1R, which 
can now be associated with insulin secretion, inhibition of glucagon secretion, slowed 
gastric emptying, increased fullness, and relaxation of gastrointestinal smooth muscle. 
Perhaps pharmacologically addressing the signal cascade initiated by Gαs activation 
could elucidate methods to increase the practical efficacy of incretin therapy.  
 In addition, it is known that agonist-bound GPCRs undergo multiple 
conformational changes while transitioning between their inactive and active forms. It 
has been suggested that allosteric interactions at the cytoplasmic aspect of GPCRs induce 
conformational changes that alter ligand-binding affinity. The potential to form active 
complexes of G protein, agonist, and receptor with enhanced stability and duration has 
great potential for therapeutic use of incretins, especially considering the short half-life of 
peptide hormones like GLP-1 (Duc, 2017). 
 This study identified expression in the colon and small intestine, but further 
research should be done to quantify relative levels of GLP-1R in mucosa and muscle of 
each organ and across different regions of the GI tract. The current research did not test 
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differences in response between distal and proximal regions of the colon and small 
intestine, nor did it quantify expression. Spatiotemporal mapping could be done to 
observe luminal behavior during GLP-1 induced relaxation. In addition, more focus could 
be allocated to comparing different isoforms of the bioactive GLP-1 peptide in different 
tissue types to compare responses. The minimal concentration of GLP-1 (7-36) amide at 
which a response was observed (threshold dose) was 10 nM with more dramatic 
responses occurring at 1 μM, but little else is known about dose-dependent responses to 
GLP-1. Propulsion studies could also be done with GLP-1 administered to different GI 
regions to observe effects on the peristaltic response.  
 When more is understood about the direct and indirect effects of GLP-1, 
expression in all tissue types has been determined, and the characteristics of its analogues 
and GLP1-R agonists have been identified, clinicians will have a valuable pathway to 
manipulate for therapeutic benefit.  A drug that induces a constant, longer-lasting GLP-
1R response will significantly impact treatment of diabetic and obese patients. Route of 
administration and dosage plans need to be determined. Finally, long-term studies on 
safety and desensitization to treatment should be explored. 
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